BRAF and melanoma: For example, although SBDD enabled the development of vemurafenib for BRAF V600E-mutant melanoma, rapid emergence of resistance driven by MAPK pathway reactivation or alternative mutations highlights the ongoing gap between structural prediction and durable clinical efficacy (Long et al., 2014).